ePrints

Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers

Lookup NU author(s): Professor Ruth Plummer

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

There is a growing appreciation of the potential value of combining novel molecularly-targeted drugs with radiotherapy or chemoradiotherapy. Such approaches have the potential to improve locoregional disease control and cure rates across a diverse range of tumour types. In this report, we outline a rational framework for developing novel drug-radiation combinations. In doing so, we make recommendations regarding the core preclinical data sets that are required to serve as justification for studies in humans and describe potential clinical trial designs that may be adopted by investigators.

Publication metadata

Author(s): Harrington KJ, Billingham LJ, Brunner TB, Burnet NG, Chan CS, Hoskin P, Mackay RI, Maughan TS, Macdougall J, McKenna WG, Nutting CM, Oliver A, Plummer R, Stratford IJ, Illidge T, NCRI Clinical Translational Radiot

Publication type: Article

Publication status: Published

Journal: British Journal of Cancer

Year: 2011

Volume: 105

Issue: 5

Pages: 628-639

Print publication date: 19/07/2011

ISSN (print): 0007-0920

ISSN (electronic): 1532-1827

Publisher: Nature Publishing Group

URL: http://dx.doi.org/10.1038/bjc.2011.240

DOI: 10.1038/bjc.2011.240

Altmetrics

Funding

Share